fda approve intismeran autogene (v940/mrna-4157)

    Before Jan 1, 2028

    fda approve intismeran autogene (v940/mrna-4157). Best Yes near 95¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 95¢ · Best No: 10¢ · 1 platform

    • Kalshi: Yes 95¢ / No 10¢
    TRADING OPEN

    Before Jan 1, 2028

    Volume

    $846

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jan 1, 2028

    ~474 days left

    Category

    Culture

    95¢CHANCE OF YES90%10%
    Yes
    95¢
    Kalshi
    No
    10¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    kalshi
    Kalshi
    Best Yes
    Best No
    Yes
    95¢
    No
    10¢
    Vol
    $846
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Jan 1, 2028, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 95¢: exit costs ~0.33¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jan 1, 2028
    Time Left474 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In